Developer docs
API playgroundTry for free, no card

Search company profiles

CS Diagnostic

Full company profile

uuid006h6oa

Namestring
CS Diagnostic
Legal namestring
CS Diagnostics Corp. Corporation
Websiteurl
csdcorp.us
Company typeenum
Public
Founded yearint
2009
Descriptiontext

CS Diagnostics Corp. (OTCQB: CSDX), a US-domiciled holding entity within the CS Group conglomerate founded by Thomas Fahrhoefer in 2009 in Germany, develops and distributes medical-grade disinfectant products, an FDA-approved hydrogel for cancer radiotherapy, and complementary medical devices. Its core proprietary offerings are MEDUSA SDP — a smart disinfectant system in wet-wipe and liquid formats (500ml and 5-liter bulk) claiming up to 10 days of antimicrobial surface protection and 99.99% germ-kill efficacy, available in alcohol-based and alcohol-free formulations — and CS Protect-Hydrogel, a sterile pre-packaged tissue spacer for prostate cancer radiotherapy that protects healthy tissue during radiation treatment. The portfolio is rounded out by MRI/CT injectors, high-pressure syringes, MultiCSafe and DoubleCSafe tube systems, a Well+ eLearning platform, and VitaLab infection-testing solutions.

The company operates a multi-channel B2B and B2C go-to-market. Institutional clients (hospitals, gyms, schools, corporate customers) are served via direct sales and bulk logistics through DHL, while consumer markets are reached through physical retail in the UAE and Germany, online marketplaces, and a direct-to-consumer website, with FedEx Dubai handling retail deliveries. Manufacturing is outsourced to strategic partners Emirate Wet Wipes LLC and Gulf Centre Group Factory, and the company operates through wholly-owned subsidiaries CS Diagnostics Pharma GmbH (Germany), CS Interpharm LLC (UAE/GCC), and CSi Turkey. Reported headcount is 1-10 employees and the company is currently conducting a Private Placement REG D 506(c) offering.

Revenue is not disclosed and MEDUSA SDP is described as recently transitioning from development to commercial production (January 2026). Pricing is quote-based for institutional accounts and unit-based for consumer channels, with no public price points. The company pursues a hybrid segmentation across healthcare institutions, fitness and education facilities, oncology/radiotherapy, luxury hospitality (Ritz-Carlton Dubai as a flagship reference), and government health ministries (Zimbabwe engagement). US public-company reporting infrastructure is being built via a PCAOB-registered auditor appointment for 2025 group financials.

Short descriptiontext

CS Diagnostics Corp. (CSDX) develops and distributes the MEDUSA smart disinfectant system, the FDA-approved CS Protect-Hydrogel for prostate cancer radiotherapy, and complementary medical devices, serving healthcare institutions, fitness and education facilities, luxury hospitality, and government health ministries globally through multi-channel B2B and B2C distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNeuss, Germany
HQ citystring
Neuss
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device manufacturing, infection control products, disinfectant solutions, pharmaceutical distribution, radiotherapy accessories
Industry1 code
PRIMARYCRADALAK
Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Paper Goods & Disposables (Tissue, Diapers, Feminine Care)
NAICS code3 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Medical Devices and Infection Control
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1MEDUSA SDP Product Sales
TypeHardware Sales
Description

Sale of medical-grade wet wipes and liquid disinfectants through institutional B2B and consumer B2C channels. Products manufactured by partners Emirate Wet Wipes LLC and Gulf Centre Group Factory. Distribution via retail stores in UAE and Germany, online marketplaces, and direct-to-consumer website.

stocktitan.net
2Pharmaceutical Distribution
TypeTransaction Fee
Description

Wholesale distribution of pharmaceuticals and medical devices through CS Diagnostics Pharma GmbH. Company plays role in healthcare supply chain ensuring widespread access to essential medications with over 25 years of sales experience.

csdcorp.us
3Medical Technology Products
TypeHardware Sales
Description

Sale of proprietary medical technology products including injectors for MRI and CT, high-pressure syringes, MultiCSafe and DoubleCSafe tube systems, and CS Protect-Hydrogel for cancer treatment.

csdcorp.us
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D
Pricing details2 tiers
1Institutional B2B pricing (hospitals, gyms, schools)
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for institutional clients. No specific pricing tiers disclosed publicly.

csdcorp.us
2Consumer B2C pricing (retail and online)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products distributed through retail stores in UAE and Germany plus online marketplaces. No specific price points disclosed.

csdcorp.us
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MEDUSA SDP
Description

Smart disinfectant product line - medical-grade wet wipes and liquid disinfectants that provide up to 10 days of protection against bacteria, viruses, and fungi. Available in alcohol-based and alcohol-free formulations.

csdcorp.us
+1 more record
Core offering1 text field

CS Diagnostics Corp. develops, manufactures, and distributes proprietary medical products including the MEDUSA SDP smart disinfectant system (medical-grade wet wipes and liquid disinfectants providing up to 10 days of antimicrobial surface protection) and CS Protect-Hydrogel (an FDA-approved hydrogel tissue spacer for prostate cancer radiotherapy). The company also distributes complementary medical devices such as MRI/CT injectors, high-pressure syringes, and tube systems, alongside pharmaceutical wholesale distribution through its German subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • MEDUSA proven effective for up to 10 days surface protection
+2 more records
Product overview1 text field

CS Diagnostics Corp. offers a diversified medical technology portfolio centered around two core products: MEDUSA SDP (a smart disinfectant system with medical-grade wet wipes and liquid formulations providing up to 10 days of surface protection) and CS Protect-Hydrogel (FDA-approved hydrogel tissue spacer for prostate cancer radiotherapy protection). The company also supplies complementary medical devices including MRI/CT injectors, high-pressure syringes, and tube systems (MultiCSafe, DoubleCSafe), alongside the Well+ eLearning platform for medical professionals and VitaLab infection testing solutions. The portfolio serves healthcare, institutional, and consumer markets globally through wholesale distribution and strategic partnerships.

Product and service1 record
1MEDUSA SDP
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeOthersAnnounced on2026-02-11
Description

Dubai-based PCAOB-registered audit firm appointed to consolidate and audit the Group's 2025 financial statements for CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. Engagement part of strategy to strengthen financial governance and align reporting with US public company standards.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Strategic manufacturing partnership for MEDUSA SDP product line. Emirate Wet Wipes LLC manufactures disinfectant wet wipes as part of transition from development to commercial production. Partnership marked as major commercialization milestone supporting global launch.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Strategic manufacturing partnership for MEDUSA SDP product line. Gulf Centre Group Factory produces bulk liquid formulations in 500ml and 5-liter formats. Partnership marked as major commercialization milestone supporting global launch across healthcare, institutional, and consumer markets.

Strategic tierCoreTypeOthersAnnounced on2026-01-21
Description

Corporate structure includes CS Diagnostics Corp. (US), CS Interpharm GT LLC (UAE/GCC), CS Diagnostics Pharma GmbH (Germany), and CSi Turkey. Group companies collaborate on product development, distribution, and regulatory approval processes across multiple regions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-01
Description

CSinterpharm partnered with FedEx Dubai combining worldwide logistics and shipping capabilities with CSinterpharm's expertise in medical supplies. Partnership focuses on faster, safer, and more efficient delivery of advanced medical innovations around the world. FedEx's extensive infrastructure and advanced technology strengthens CSinterpharm's distribution network, reduces transit times, and ensures safe delivery to even remote locations.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

CSinterpharm partnership with The Ritz-Carlton Dubai for first delivery of MEDUSA smart disinfectant product. Collaboration marks beginning of promising long-term partnership poised to transform hygiene standards in hospitality industry. Initial delivery of 25 one-liter bottles for demonstration. Eco-friendly MEDUSA supports hotel's sustainability initiatives.

7Zimbabwe Embassy in UAE
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Chairman Thomas Fahrhoefer visited Zimbabwe Embassy in Abu Dhabi to discuss healthcare initiatives supporting Zimbabwe's healthcare infrastructure. Presentations included MEDUSA smart disinfectant, VitaLab test solutions, and medical care product delivery. Part of initiative for international cooperation and innovative healthcare solutions for underserved regions.

csdcorp.us
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

CSinterpharm is a proud supporter of the Dubai Club for People of Determination. CS Group's regional arm contributes to community betterment by supporting initiatives that promote wellness and development in healthcare and sports. Collaboration reflects shared vision of improving quality of life for individuals with disabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1McKesson
TypeBroad incumbent
Description

McKesson is a global pharmaceutical and medical-product wholesaler that competes with CS Diagnostics Pharma GmbH's pharmaceutical distribution business across Europe and adjacent markets.

TypeDirect peer
Description

GOJO Industries, maker of Purell, is a focused player in healthcare and institutional hand hygiene and surface disinfection, directly comparable to MEDUSA SDP in the infection-prevention use case.

TypeDirect peer
Description

Guerbet is a specialized contrast media and injector manufacturer for radiology, directly comparable to CS Diagnostics' MRI/CT injectors and high-pressure syringes for imaging workflows.

TypeBroad incumbent
Description

3M's Health Care division spans infection prevention, drug delivery, and medical supplies, creating overlapping offerings with MEDUSA SDP surface disinfection and CS Diagnostics' broader medical device catalog.

TypeBroad incumbent
Description

Reckitt owns Lysol and Dettol, the dominant consumer disinfectant brands globally; it represents the incumbent benchmark CS Diagnostics' MEDUSA SDP must differentiate against in retail and institutional channels.

TypeEmerging player
Description

Palette Life Sciences markets Barrigel, another rectal spacer hydrogel for prostate radiotherapy; it is an emerging competitor in the same niche use case as CS Protect-Hydrogel.

TypeDirect peer
Description

Boston Scientific markets SpaceOAR, an FDA-approved hydrogel spacer for prostate cancer radiotherapy, which directly competes with CS Diagnostics' CS Protect-Hydrogel in the same indication and clinical use case.

TypeDirect peer
Description

Ecolab is a global leader in institutional disinfection and hygiene solutions for healthcare, hospitality, and food service — markets where CS Diagnostics is positioning MEDUSA SDP as a long-acting alternative.

TypeDirect peer
Description

Bayer's Medrad division manufactures MRI and CT contrast injectors, which are direct competitors to the MRI/CT injectors and high-pressure syringes in CS Diagnostics' medical device portfolio.

TypeBroad incumbent
Description

Clorox is a broad incumbent in disinfectants and surface sanitization, with a comparable consumer and institutional disinfectant portfolio competing for the same shelf and contract slots targeted by MEDUSA SDP.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CS Diagnostic

Medical Devices and Infection Controlcsdcorp.us

CS Diagnostics Corp. (CSDX) develops and distributes the MEDUSA smart disinfectant system, the FDA-approved CS Protect-Hydrogel for prostate cancer radiotherapy, and complementary medical devices, serving healthcare institutions, fitness and education facilities, luxury hospitality, and government health ministries globally through multi-channel B2B and B2C distribution.

What CS Diagnostic does

CS Diagnostics Corp. (OTCQB: CSDX), a US-domiciled holding entity within the CS Group conglomerate founded by Thomas Fahrhoefer in 2009 in Germany, develops and distributes medical-grade disinfectant products, an FDA-approved hydrogel for cancer radiotherapy, and complementary medical devices. Its core proprietary offerings are MEDUSA SDP — a smart disinfectant system in wet-wipe and liquid formats (500ml and 5-liter bulk) claiming up to 10 days of antimicrobial surface protection and 99.99% germ-kill efficacy, available in alcohol-based and alcohol-free formulations — and CS Protect-Hydrogel, a sterile pre-packaged tissue spacer for prostate cancer radiotherapy that protects healthy tissue during radiation treatment. The portfolio is rounded out by MRI/CT injectors, high-pressure syringes, MultiCSafe and DoubleCSafe tube systems, a Well+ eLearning platform, and VitaLab infection-testing solutions.

The company operates a multi-channel B2B and B2C go-to-market. Institutional clients (hospitals, gyms, schools, corporate customers) are served via direct sales and bulk logistics through DHL, while consumer markets are reached through physical retail in the UAE and Germany, online marketplaces, and a direct-to-consumer website, with FedEx Dubai handling retail deliveries. Manufacturing is outsourced to strategic partners Emirate Wet Wipes LLC and Gulf Centre Group Factory, and the company operates through wholly-owned subsidiaries CS Diagnostics Pharma GmbH (Germany), CS Interpharm LLC (UAE/GCC), and CSi Turkey. Reported headcount is 1-10 employees and the company is currently conducting a Private Placement REG D 506(c) offering.

Revenue is not disclosed and MEDUSA SDP is described as recently transitioning from development to commercial production (January 2026). Pricing is quote-based for institutional accounts and unit-based for consumer channels, with no public price points. The company pursues a hybrid segmentation across healthcare institutions, fitness and education facilities, oncology/radiotherapy, luxury hospitality (Ritz-Carlton Dubai as a flagship reference), and government health ministries (Zimbabwe engagement). US public-company reporting infrastructure is being built via a PCAOB-registered auditor appointment for 2025 group financials.

CS Diagnostic firmographics

Firmographics
Name
CS Diagnostic
Legal name
CS Diagnostics Corp. Corporation
Website
https://csdcorp.us
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
CS Diagnostics Corp. (CSDX) develops and distributes the MEDUSA smart disinfectant system, the FDA-approved CS Protect-Hydrogel for prostate cancer radiotherapy, and complementary medical devices, serving healthcare institutions, fitness and education facilities, luxury hospitality, and government health ministries globally through multi-channel B2B and B2C distribution.
Ownership category
akta.pro rank

CS Diagnostic industry classification

Industry
Product category
Medical Devices and Infection Control
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYCRADALAK
Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Paper Goods & Disposables (Tissue, Diapers, Feminine Care)

Keywords

  • Medical device manufacturing
  • Infection control products
  • Disinfectant solutions
  • Pharmaceutical distribution
  • Radiotherapy accessories

Where CS Diagnostic is headquartered

Location

Headquarters

HQ city
Neuss
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

CS Diagnostic business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D

Revenue model

  1. MEDUSA SDP Product Sales: Sale of medical-grade wet wipes and liquid disinfectants through institutional B2B and consumer B2C channels. Products manufactured by partners Emirate Wet Wipes LLC and Gulf Centre Group Factory. Distribution via retail stores in UAE and Germany, online marketplaces, and direct-to-consumer website.
  2. Pharmaceutical Distribution: Wholesale distribution of pharmaceuticals and medical devices through CS Diagnostics Pharma GmbH. Company plays role in healthcare supply chain ensuring widespread access to essential medications with over 25 years of sales experience.
  3. Medical Technology Products: Sale of proprietary medical technology products including injectors for MRI and CT, high-pressure syringes, MultiCSafe and DoubleCSafe tube systems, and CS Protect-Hydrogel for cancer treatment.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInstitutional B2B pricing (hospitals, gyms, schools)
Unit PricingPay-as-you-goConsumer B2C pricing (retail and online)

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

CS Diagnostic product offering

Product offering

Core offering

CS Diagnostics Corp. develops, manufactures, and distributes proprietary medical products including the MEDUSA SDP smart disinfectant system (medical-grade wet wipes and liquid disinfectants providing up to 10 days of antimicrobial surface protection) and CS Protect-Hydrogel (an FDA-approved hydrogel tissue spacer for prostate cancer radiotherapy). The company also distributes complementary medical devices such as MRI/CT injectors, high-pressure syringes, and tube systems, alongside pharmaceutical wholesale distribution through its German subsidiary.

Product overview

CS Diagnostics Corp. offers a diversified medical technology portfolio centered around two core products: MEDUSA SDP (a smart disinfectant system with medical-grade wet wipes and liquid formulations providing up to 10 days of surface protection) and CS Protect-Hydrogel (FDA-approved hydrogel tissue spacer for prostate cancer radiotherapy protection). The company also supplies complementary medical devices including MRI/CT injectors, high-pressure syringes, and tube systems (MultiCSafe, DoubleCSafe), alongside the Well+ eLearning platform for medical professionals and VitaLab infection testing solutions. The portfolio serves healthcare, institutional, and consumer markets globally through wholesale distribution and strategic partnerships.

Differentiator

Problem solved

Functional benefit

Brands

  • MEDUSA SDP: Smart disinfectant product line - medical-grade wet wipes and liquid disinfectants that provide up to 10 days of protection against bacteria, viruses, and fungi. Available in alcohol-based and alcohol-free formulations.
  • CS Protect-Hydrogel

Products and services

  • MEDUSA SDP

Quantifiable outcome

  • MEDUSA proven effective for up to 10 days surface protection
  • +2 more outcomes

Companies that use CS Diagnostic

Customer profile

Named customers3 records

Segments6 records

Ideal customer profiles6 records

CS Diagnostic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CS Diagnostic partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, core and flagship.

  • Shah Teelani & AssociatesminorOthers · 11 February 2026Dubai-based PCAOB-registered audit firm appointed to consolidate and audit the Group's 2025 financial statements for CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. Engagement part of strategy to strengthen financial governance and align reporting with US public company standards.
  • Emirate Wet Wipes LLCcoreStrategic or Co-development Partner · 29 January 2026Strategic manufacturing partnership for MEDUSA SDP product line. Emirate Wet Wipes LLC manufactures disinfectant wet wipes as part of transition from development to commercial production. Partnership marked as major commercialization milestone supporting global launch.
  • Gulf Centre Group FactorycoreStrategic or Co-development Partner · 29 January 2026Strategic manufacturing partnership for MEDUSA SDP product line. Gulf Centre Group Factory produces bulk liquid formulations in 500ml and 5-liter formats. Partnership marked as major commercialization milestone supporting global launch across healthcare, institutional, and consumer markets.
  • CS Group SubsidiariescoreOthers · 21 January 2026Corporate structure includes CS Diagnostics Corp. (US), CS Interpharm GT LLC (UAE/GCC), CS Diagnostics Pharma GmbH (Germany), and CSi Turkey. Group companies collaborate on product development, distribution, and regulatory approval processes across multiple regions.
  • FedEx DubaicoreChannel Partner/ Reseller/ Distributor · 1 March 2025CSinterpharm partnered with FedEx Dubai combining worldwide logistics and shipping capabilities with CSinterpharm's expertise in medical supplies. Partnership focuses on faster, safer, and more efficient delivery of advanced medical innovations around the world. FedEx's extensive infrastructure and advanced technology strengthens CSinterpharm's distribution network, reduces transit times, and ensures safe delivery to even remote locations.
  • The Ritz-Carlton DubaiflagshipStrategic or Co-development Partner · 1 March 2025CSinterpharm partnership with The Ritz-Carlton Dubai for first delivery of MEDUSA smart disinfectant product. Collaboration marks beginning of promising long-term partnership poised to transform hygiene standards in hospitality industry. Initial delivery of 25 one-liter bottles for demonstration. Eco-friendly MEDUSA supports hotel's sustainability initiatives.
  • Zimbabwe Embassy in UAEminorStrategic or Co-development Partner · 1 January 2025Chairman Thomas Fahrhoefer visited Zimbabwe Embassy in Abu Dhabi to discuss healthcare initiatives supporting Zimbabwe's healthcare infrastructure. Presentations included MEDUSA smart disinfectant, VitaLab test solutions, and medical care product delivery. Part of initiative for international cooperation and innovative healthcare solutions for underserved regions.
  • Dubai Club for People of DeterminationminorOthers · 1 January 2024CSinterpharm is a proud supporter of the Dubai Club for People of Determination. CS Group's regional arm contributes to community betterment by supporting initiatives that promote wellness and development in healthcare and sports. Collaboration reflects shared vision of improving quality of life for individuals with disabilities.

Scale indicators5 records

Recent moves7 records

Expansion highlights7 records

CS Diagnostic competitors and assessment

Company assessment

Broad incumbents

  • McKesson: McKesson is a global pharmaceutical and medical-product wholesaler that competes with CS Diagnostics Pharma GmbH's pharmaceutical distribution business across Europe and adjacent markets.
  • 3M Health Care: 3M's Health Care division spans infection prevention, drug delivery, and medical supplies, creating overlapping offerings with MEDUSA SDP surface disinfection and CS Diagnostics' broader medical device catalog.
  • Reckitt Benckiser: Reckitt owns Lysol and Dettol, the dominant consumer disinfectant brands globally; it represents the incumbent benchmark CS Diagnostics' MEDUSA SDP must differentiate against in retail and institutional channels.
  • Clorox Company: Clorox is a broad incumbent in disinfectants and surface sanitization, with a comparable consumer and institutional disinfectant portfolio competing for the same shelf and contract slots targeted by MEDUSA SDP.

Direct peers

  • GOJO Industries: GOJO Industries, maker of Purell, is a focused player in healthcare and institutional hand hygiene and surface disinfection, directly comparable to MEDUSA SDP in the infection-prevention use case.
  • Guerbet: Guerbet is a specialized contrast media and injector manufacturer for radiology, directly comparable to CS Diagnostics' MRI/CT injectors and high-pressure syringes for imaging workflows.
  • Boston Scientific: Boston Scientific markets SpaceOAR, an FDA-approved hydrogel spacer for prostate cancer radiotherapy, which directly competes with CS Diagnostics' CS Protect-Hydrogel in the same indication and clinical use case.
  • Ecolab: Ecolab is a global leader in institutional disinfection and hygiene solutions for healthcare, hospitality, and food service — markets where CS Diagnostics is positioning MEDUSA SDP as a long-acting alternative.
  • Bayer (Medrad): Bayer's Medrad division manufactures MRI and CT contrast injectors, which are direct competitors to the MRI/CT injectors and high-pressure syringes in CS Diagnostics' medical device portfolio.

Emerging players

  • Palette Life Sciences: Palette Life Sciences markets Barrigel, another rectal spacer hydrogel for prostate radiotherapy; it is an emerging competitor in the same niche use case as CS Protect-Hydrogel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

CS Diagnostic social profiles

Digital presence

CS Diagnostic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CS Diagnostic leadership team

Management profile

Number of profiles

Profiles2 records

CS Diagnostic subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

CS Diagnostic funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CS Diagnostic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CS Diagnostic

What does CS Diagnostic do?

CS Diagnostics Corp. develops, manufactures, and distributes proprietary medical products including the MEDUSA SDP smart disinfectant system (medical-grade wet wipes and liquid disinfectants providing up to 10 days of antimicrobial surface protection) and CS Protect-Hydrogel (an FDA-approved hydrogel tissue spacer for prostate cancer radiotherapy). The company also distributes complementary medical devices such as MRI/CT injectors, high-pressure syringes, and tube systems, alongside pharmaceutical wholesale distribution through its German subsidiary.

Is CS Diagnostic a public or private company?

CS Diagnostic is a public company. It is classified as public and is currently operating.

When was CS Diagnostic founded?

CS Diagnostic was founded in 2009. It employs 1 to 10 people.

Where is CS Diagnostic based?

CS Diagnostic is headquartered in Neuss, Germany, in the Europe region.

How does CS Diagnostic make money?

Three revenue lines are on record. MEDUSA SDP Product Sales are the primary driver. The others are pharmaceutical Distribution and medical Technology Products.

Who are CS Diagnostic's main competitors?

Broad incumbents on record are McKesson, 3M Health Care, Reckitt Benckiser and Clorox Company. Direct peers are GOJO Industries, Guerbet, Boston Scientific, Ecolab and Bayer (Medrad). Palette Life Sciences is listed as an emerging player.

Does CS Diagnostic have an API?

No public API is recorded for CS Diagnostic.

What industry is CS Diagnostic in?

CS Diagnostic's product category is Medical Devices and Infection Control. Its primary akta.pro industry code is CRADALAK, Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanCS Group hires PCAOB auditor for 2025 accountsCS Diagnostics Corp. (OTCQB: CSDX) announced the appointment of Shah Teelani & Associates, a Dubai-based PCAOB-registered audit firm, to consolidate and audit the Group's 2025 financial statements for CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. The engagement is part of CS Group's strategy to strengthen financial governance, align reporting with US public company standards, and support its international expansion across the United States, GCC region, and Europe. Management stated this appointment enhances transparency, regulatory compliance, and investor confidence as the company scales operations globally.GlobeNewswireCS Group (OTCQB: CSDX) Secures Strategic Manufacturing Partnerships, Accelerating Global Commercial Launch of MEDUSA SDP Hygiene ProductsCS Diagnostics Corp. confirmed strategic manufacturing partnerships with Emirate Wet Wipes and Gulf Centre Group Factory to produce MEDUSA SDP hygiene products. The agreements provide scalable capacity and compliance, accelerating the global launch of the disinfectant wet wipes and liquid formulations. Management stated this is a pivotal step toward full-scale commercial production.Stock TitanCS Diagnostics inks MEDUSA SDP manufacturing dealsCS Diagnostics Corp. announced strategic manufacturing partnerships with Emirate Wet Wipes LLC and Gulf Centre Group Factory to produce its MEDUSA SDP product line of medical-grade wet wipes and liquid disinfectants, marking a transition from development to commercial production. Emirate Wet Wipes LLC will manufacture disinfectant wet wipes while Gulf Centre Group Factory will produce bulk liquid formulations in 500ml and 5-liter formats. The partnerships are positioned as a major commercialization milestone supporting global launch across healthcare, institutional, and consumer markets in the GCC region and Europe.GlobeNewswireCS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDPCS Diagnostics Corp. announced a multi-channel sales model for MEDUSA SDP, covering B2B and B2C channels, with DHL and FedEx as logistics partners. The company plans to begin regulatory approval for a bio-degradable, dissolving wet wipes line, advancing its sustainability strategy.GlobeNewswireCS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDPCS Diagnostics Corp announced its multi-channel sales strategy for the MEDUSA SDP hygiene product, targeting both institutional (hospitals, gyms, schools, corporate clients) and consumer markets through retail stores in UAE and Germany, online marketplaces, and a direct-to-consumer website. The company has engaged DHL for bulk and institutional shipments while FedEx will manage retail and consumer-focused deliveries. Management stated the company expects to begin regulatory approval processes for a biodegradable version of the product line as part of its long-term sustainability strategy.GlobeNewswireCS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDPCS Diagnostics Corp. (OTCQB: CSDX) announced its multi-channel sales strategy for the MEDUSA SDP hygiene platform, targeting both institutional B2B clients and consumer B2C markets across physical retail and online marketplaces. The company has established global logistics partnerships with DHL handling bulk institutional shipments and FedEx managing retail deliveries, while also outlining plans to pursue regulatory approval for a biodegradable, dissolving wet wipes product line.Stock TitanCS Group outlines MEDUSA SDP global sales, logisticsCS Diagnostics Corp announced its multi-channel sales strategy and global logistics partnerships for the MEDUSA SDP disinfectant product, selecting DHL for bulk institutional shipments and FedEx for retail deliveries. The company outlined plans to distribute through B2B channels including hospitals, gyms, and schools, and B2C channels across physical retail in UAE and Germany plus online marketplaces. The company also indicated it expects to begin regulatory approval processes for a biodegradable wet wipes line as part of its sustainability roadmap.FinancialContent Business PageCS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI InsideCS Diagnostics Corp. (OTCQB: CSDX) is positioning itself as a dual-focus medical technology company targeting hospital infection prevention and cancer treatment support, with its portfolio including the MEDUSA smart disinfectant system and CS Protect-Hydrogel tissue spacer for radiotherapy protection. The article draws comparisons between CSDX's innovation strategy and regulatory pathways pursued by larger NASDAQ-listed peers such as Exact Sciences, Castle Biosciences, Guardant Health, Accuray, and Co-Diagnostics. The piece characterizes CSDX as a micro-cap healthcare company aligned with durable medical technology trends heading into 2026, though no specific product milestones, regulatory approvals, or financial developments are reported.NewswireCS Diagnostics Corp. Launches Regulation D, Rule 506(c) Investment OfferingCS Diagnostics Corp. launched a Regulation D, Rule 506(c) investment offering open to U.S. accredited and non-U.S. investors. Proceeds will fund commercialization of CS Protect Hydrogel and MEDUSA, with allocations for regulatory, manufacturing, and sales. The company expects substantial growth and long-term returns.